Evidence map›Paper›PMID 34890242›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on.

Ramya Ramaswami, Kathryn Lurain, Robert Yarchoan

Open access · greenAbstract readReview
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ramya RamaswamiHIV and AIDS Malignancy Branch, Center for Cancer Research, NCI, Bethesda, MD.ORCID 0000-0001-5709-4675
Kathryn LurainHIV and AIDS Malignancy Branch, Center for Cancer Research, NCI, Bethesda, MD.ORCID 0000-0002-5794-7292
Robert YarchoanHIV and AIDS Malignancy Branch, Center for Cancer Research, NCI, Bethesda, MD.
Center for Cancer Research · US

Funding

Clinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$20.6M
Targeted therapies for Kaposi sarcoma and KSHV-multicentric Castleman diseaseZIABC011954 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RAMASWAMI, RAMYA · 2020 to 2025
$3.8M
6 · The paper itself

Abstract

The observation in 1981 of the emergence of Kaposi sarcoma (KS) among young men who had sex with men was one of the first harbingers of the HIV epidemic. With advances in HIV care, the incidence of HIV-associated KS (HIV

Indexed as

HIV InfectionsImmunotherapyAntineoplastic AgentsDiffusion of InnovationHumansMedical OncologyMolecular Targeted TherapySarcoma, KaposiTreatment OutcomeAntineoplastic Agents

Identifiers

PMID34890242
PMCPMC8769148
OpenAlexW4200229516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.